Linezolid versus vancomycin for skin and soft tissue infections

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Yue, Jirong ^a   Dong, Bi Rong ^a   Yang, Ming ^a   Chen, Xiaomei ^a   Wu, Taixiang ^a   Liu, Guan J ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; LINEZOLID; VANCOMYCIN;

ANTIBIOTIC THERAPY; CLINICAL PROTOCOL; CLINICAL RESEARCH; DATA ANALYSIS; HUMAN; METHODOLOGY; OUTCOME ASSESSMENT; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION;

EID: 77950129835     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008056     Document Type: Review

References (22)

1. Bouza 2004 Bouza E, Sousa D, Muñoz P, Rodríguez- Créixems M, Fron C, Lechuz JG. Bloodstream infections: a trial of the impact of different methods of reporting positive blood culture results. Journal of Infectious Diseases 2004;39(8):1161-9.
2. Donner 2001 Donner A, Piaggio G, Villar J. Statistical methods for the meta analysis of cluster randomization trials. Statistical Methods in Medical Research 2001;10(5):325-38.
3. Eisenstein 2008 Eisenstein BI. Treatment challenges in the management of complicated skin and soft-tissue infections. Clinical Microbiology and Infection 2008;14(Suppl 2):17-25.
4. Engemann 2003 Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL, et al.Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clinical Infectious Diseases 2003;36(5):592-8.
5. Eron 2003 Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA. Managing skin and soft tissue infections: expert panel recommendations on key decision points. Journal of Antimicrobial Chemotherapy 2003;52(suppl 1):i3-i17.
6. FDA 1998 FDA. Uncomplicated and complicated skin and skin structure infections - developing antimicrobial drugs for treatment. Guidance for Industry: Center for Drug Evaluation and Research (CDER). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm071185.pdf 1998.
7. Finch 2005 Finch RG, Eliopoulos GM. Safety and efficacy of glycopeptide antibiotics. Journal of Antimicrobial Chemotherapy 2005;55(suppl 2):ii5-ii13.
8. Fritsche 2007 Fritsche TR, Sader HS, Jones RN. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). Diagnostic Microbiology and Infectious Disease 2007;58(1):19-26.
9. Fung 2001 Fung HB, Kirschenbaum HL, Ojofeitimi BO. Linezolid: an oxazolidinone antimicrobial agent. Clinical Therapeutics 2001;23 (3):356-91.
10. Fung 2003 Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 2003;63(14):1459-80.
11. Higgins 2008a Jonathan J Deeks, Julian PT Higgins and Douglas G Altman on behalf of the Cochrane Statistical Methods Group (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008).The CochraneCollaboration, 2008. Available from www.cochrane-handbook.org.
12. Higgins 2008b Jonathan J Deeks, Julian PT Higgins and Douglas G Altman on behalf of the Cochrane StatisticalMethods Group (editors). Chapter16: Special topics in statistics. In: Higgins JPT, Green S (editors). CochraneHandbook for SystematicReviews of InterventionsVersion5.0.0 (updated February 2008).The Cochrane Collaboration, 2008.Available from www.cochrane-handbook.org.
13. Lamagni 2008 Lamagni TL, Darenberg J, Luca-Harari B, Siljander T, Efstratiou A, Henriques-Normark B, et al.Epidemiology of severe Streptococcus pyogenes disease in Europe. Journal of clinical microbiology 2008;46 (7):2359-67.
14. Lefebvre 2008 Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008.
15. McEvoy 1997 McEvoy GK, editor. American Hospital Formulary Service Drug Information 1997. American Society of Health-System Pharmacists.
16. Moellering 1999 Moellering RC Jr. A novel antimicrobial agent joins the battle against resistant bacteria. Annals of Internal Medicine 1999;130(2): 155-7.
17. Moet 2006 Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagnostic Microbiology and Infectious Disease 2007;57(1):7-13.
18. Perry 2000 Perry CM, Jarvis B. Linezolid: A review of its use in antimicrobial resistances (R) from the SENTRY Antimicrobial Surveillance Program (Abstract). Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada. 2000:86.
19. SIGN 2008 Scottish Intercollegiate Guidelines Network (SIGN). Search filters. http://www.sign.ac.uk/methodology/filters.html#random (accessed 27 May 2008).
20. Stevens 2002 Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, HafkinB. Linezolid versus vancomycin for the treatment of methicillinresistantStaphylococcus aureus infections. Clinical Infectious Diseases 2002;34(11):1481-90.
21. Stevens 2005 Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, et al.Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clinical Infectious Diseases 2005;41(10):1373-406.
22. Wunderink 2003 Wunderink RG, Rello J, Cammarata S, Croos-Dabrera RV, KollefMH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124(5):1789-97.